Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGSWW) Research & Development (2020 - 2025)

GeneDx Holdings has reported Research & Development over the past 6 years, most recently at $24.5 million for Q4 2025.

  • Quarterly results put Research & Development at $24.5 million for Q4 2025, up 111.78% from a year ago — trailing twelve months through Dec 2025 was $72.0 million (up 57.53% YoY), and the annual figure for FY2025 was $72.0 million, up 57.53%.
  • Research & Development for Q4 2025 was $24.5 million at GeneDx Holdings, up from $19.8 million in the prior quarter.
  • Over the last five years, Research & Development for WGSWW hit a ceiling of $53.1 million in Q1 2021 and a floor of $10.9 million in Q2 2024.
  • Median Research & Development over the past 5 years was $14.8 million (2023), compared with a mean of $18.4 million.
  • Peak annual rise in Research & Development hit 127.31% in 2022, while the deepest fall reached 59.88% in 2022.
  • GeneDx Holdings' Research & Development stood at $22.2 million in 2021, then rose by 9.53% to $24.4 million in 2022, then tumbled by 49.73% to $12.2 million in 2023, then fell by 5.39% to $11.6 million in 2024, then surged by 111.78% to $24.5 million in 2025.
  • The last three reported values for Research & Development were $24.5 million (Q4 2025), $19.8 million (Q3 2025), and $15.1 million (Q2 2025) per Business Quant data.